72 results about "Management of depression" patented technology

The present invention is an improvement in the treatment of mania and depression by administering topiramate in a sustained-release formulation. The sustained-release formulation of the present invention may also be co-administered with anti-psychotics and anti-depressants.

Substituted 3-pyrrolidine-indole derivatives and methods for their production. Also pharmaceutical compositions containing these compounds and the use of these substances in methods of treatment, in particular treatment of pain and / or depression.

The invention provides a compound of formula (I):wherein R1, R2, R3, and Y have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease or depression comprising administering a compound of formula I, to a mammal in need of such treatment.

It has been found that the treatment of depression using known serotonin reuptake inhibitors (SRIs) and noradrenaline reuptake inhibitors (NRIs) may be improved by the administration therewith of folic acid or a precursor which produces folate in the patient. The daily dose of NRI or SRI is as prescribed for treatment of depression in the usual way. The daily dose of the folic acid or precursor should be such as to provide a folate dosage of 300-5000 micrograms / day.

The invention provides a compound of formula (I): wherein R1, R2, R3, and Y have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease or depression comprising administering a compound of formula I, to a mammal in need of such treatment.

A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of eicosapentanoic acid ethyl ester (EPA), of docosahexaenoic acid ethyl ester (DHA), or of a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), especially a mixture of EPA and DHA in an EPA / DHA ratio in the range from about 0.9 to about 1.5 at a dosage of from about 0.7 g to about 6 g per day.

Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula I: or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, R4, R5, R6, n, and m are as defined and described herein.

Materials and Methods for stratifying disease severity and for monitoring major depressive disorder are provided.

The present invention provides a solid medicine combination, which comprises ago cherating as an active ingredient; a non-ionic hydrophilic surfactant which can be accepted by pharmacy. In addition, the present invention is combined with one or a plurality of medicine excipients. The present invention is mainly used for curing depression.

A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C / C DNA sequence in the 5-HT2A receptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.

The invention relates to application of a 20(S)-ginsenoside Rh2, namely 3-O-beta-D-glycopyranoside-dammarane-24-alkenyl-3beta, 12beta, 20(S)-triol compound in the field of pharmacy. The compound can effectively confront reserpine related ptosis or akinesia, L-5-HT related mouse tremble, mouse suspension tail or forced swimming acquired desperation and depression and enhance levodopa behavioral effects under test dose, and has no excitation or inhibition function on central pivot. The safety research shows that the compound has high safety, does not influence the central nervous system, cardiovascular system and respiratory system, and has no mutagenesis function. The compound has high safety and good antidepressant function under the test dose, and the action mechanism of the compound can block the reuptake of NA and DA transmitter so as to increase the concentration correlation of two transmitters of synapse and clearance; and the compound can be used for treating depression.

The invention discloses a medicine for treating depression, and a preparation method thereof. The medicine is prepared from bupleurum chinense, root of red-rooted salvia, acorus gramineus, thinleaf milkwort rootbark, zedoary, coptis chinensis, dragon bone, oyster, and chlorite schist in a certain weight part proportion; bupleurum chinense, root of red-rooted salvia, acorus gramineus, thinleaf milkwort rootbark, zedoary and coptis chinensis are extracted by a percolation method, dragon bone, oyster, and chlorite schist are extracted by a levigation method, then extracts are mixed, and mixed extracts and auxiliary materials are mixed to be prepared into any common oral formulation. The medicine has the effects of soothing the liver and regulating vital energy, activating blood and dissolving stasis, tranquilizing the mind, reducing phlegm and purging fire and the like, is used for treating liver qi stagnation, vexation and sleeplessness and other symptoms, and is also used for treating depression.

The invention relates the gen-seng ocotillo spooning and glycoside. The gen-seng ocotillo spooning and glycoside has good central stimulating action, so it can be used to prepare mental stimulant, health products, food additives and compound recipe preparation. It is mainly used to cure paroxysmal sleep and depression. It also can be used to cure proscenia, recover fatigue, improve memory, and modify emotion.

The invention relates to a formula of a novel anti-depression compound preparation and a preparation method. The novel anti-depression compound preparation consisting of ginsenoside, valerian and Omega-3 (or fish oil) together is designed, and a proportion and a preparation mode of the compound preparation are determined. Proved in experiments, the compound preparation has anti-depression effect, has the characteristics of safety, reliability and low cost, and can be prepared into various acceptable formulations for treating and preventing depression.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

The invention discloses a tradtional Chinese medicament for treating post cerebral hemorrhage depressions, and relates to a tradtional Chinese medicament. The tradtional Chinese medicament overcomes the defect of depression of cerebral hemorrhage patients, and can promote quicker recovery of patients and reduce or eliminate great harm of depression to patients, families and the society if early application. The tradtional Chinese medicament for treating post cerebral hemorrhage depression comprises the following components in parts by weight: 35 parts of astragalus root, 25 parts of bupleurum, 25 parts of angelica, 20 parts of peach seeds, 20 parts of Szechuan lovage rhizome, 20 parts of safflower, 20 parts of frankincense, 20 parts of myrrh, 15 parts of white atractylodes rhizome, 15 parts of white peony root, 15 parts of poria cocos, 10 parts of earthworms, 10 parts of ginger, 8 parts of mint and 5 parts of honey-fried licorice root. The tradtional Chinese medicament for treating post cerebral hemorrhage depressions does not contain toxic Chinese medicinal components, does not have toxic or side effect, has low cost and can be used for treating various treating post cerebral hemorrhage depressions, the treatment course is 20-30 days, the treatment effect is good, the effective rate reaches 100%, and the cure rate reaches over 90%.

The invention provides a method for obtaining an agitated depression animal model and application thereof, and particularly provides a method for obtaining the agitated depression animal model in a non-diagnostic and non-therapeutic mode. The agitated depression animal model obtained through the method not only shows depressive behaviors, but also shows anxiety behaviors. An agitated depression treatment effect can be evaluated more effectively through the model, and the method can further be used for screening therapeutic agents for treating agitated depression.

The invention relates to applications of a compound cinnamyl-(6'-O-alpha-L-arabopyranose)-O-beta-D-glucopyranoside in pharmaceutical field. The compound can effectively resist blepharoptosis caused by reserpine or akinesia, resist small mouse thrill caused by L-5-HT, resist small mouse tail suspension or acquired desperation depression by a forced swinging method, strengthen L-dopa behavioural effect, and has no exciting or inhibiting effect to nerve centres. The action mechanism thereof may be related to breaking reuptake of NA, DA transmittances so as to increase concentration of the two transmittances in synaptic spaces. The compound has no toxic reactions in acute toxicity experiences on mice so that the compound with experience dosage has relatively high security and good anti-depression effect and can be used to treat depression.

The invention discloses an anti-depression medicine composition and an application thereof, belonging to the technical field of medicines. The medicine composition is prepared from an active component and auxiliary materials, wherein the active component comprises demethylation bellidifolin. As the demethylation bellidifolin has anti-depression biological activity, the medicine composition prepared from the demethylation bellidifolin can be used for treatment of depression.

The invention provides an application of miR-199a-3p in sperm in preparation of a depression detection product and an anti-depression drug. According to the application, miR-199a-3p in sperms is innovatively applied to a depression detection product and an antidepressant drug, depression is detected and treated based on the specific miR-199a-3p in sperms, the depression detection product can effectively improve the accuracy of depression detection and is high in detection efficiency, and the antidepressant drug can improve the treatment effect of depression and can also improve the treatment effect of sperms. The intergenerational inheritance of depression can be effectively inhibited, and large-scale popularization and application are easy.

The invention discloses traditional Chinese medicine decoction for treating depression and a preparation method of the traditional Chinese medicine decoction. The traditional Chinese medicine decoction comprises the following raw material medicines as effective components in parts by mass: 25-35 parts of poria cocos, 15-25 parts of polygala tenuifolia, 10-20 parts of cortex albiziae, 10-25 parts of tuber fleeceflower stems, 8-18 parts of husked sorghum, 12-23 parts of pearls, 11-21 parts of amber, 15-26 parts of benzoin, 6-19 parts of oyster, 5-18 parts of rhizoma corydalis, 5-15 parts of radix achyranthis bidentatae, 8-22 parts of Chinese yam, 8-23 parts of radix paeoniae alba, 10-24 parts of mulberry, 5-21 parts of paper mulberry fruit, 7-18 parts of deer-horn glue, 8-20 parts of radix pseudostellariae, 9-17 parts of black-bone chicken, 5-19 parts of rhizoma polygonati, 6-18 parts of eclipta prostrate and 7-16 parts of liquorice. By adopting the traditional Chinese medicine decoction, treatment on depression can be promoted, and the total effective rate of treatment can be greater than 98%.

The invention relates to a medicine composition for treating depression and a method for preparing the medicine composition, and belongs to the field of traditional Chinese medicines. The medicine composition comprises components including, by weight, 8-12 parts of radix ginseng, 8-12 parts of radix bupleuri, 10-14 parts of radix scutellariae, 8-12 parts of rhizoma pinelliae preparatum, 8-12 partsof ramulus cinnamomi, 8-12 parts of rhizoma zingiberis, 7-9 parts of semen ziziphi spinosae, 8-12 parts of radix curcumae, 13-17 parts of ossa draconis, 13-17 parts of concha ostreae, 3-5 parts of fructus jujubae and 8-12 parts of radix glycyrrhizae preparata. Outstanding curative effects can be realized by the various components in the weight ranges. The medicine composition and the method havethe advantages that the medicine composition comprises traditional Chinese medicines such as the radix ginseng, the radix bupleuri and the radix scutellariae, the radix ginseng is sweet in taste and slightly warm in nature and mainly acts in spleens and lung channels, the radix bupleuri is bitter in taste and slightly cold in nature and has certain pharmaceutical activity for regulating immune systems, effects of tranquilizing mind and relieving pain can be realized by the radix bupleuri, effects of clearing heat, drying dampness, stopping bleeding and preventing miscarriage can be realized bythe radix scutellariae, effects of drying dampness and resolving phlegm can be realized by the rhizoma pinelliae preparatum, obvious effects for treating the depression can be realized by the ramuluscinnamomi, the rhizoma zingiberis, the semen ziziphi spinosae and the like, and the medicine composition is applied to an accumulative number of years for the time being, is used for more than 300 cases and accordingly has solid clinical foundations and theoretical foundations.

The invention discloses a food composition capable of relieving depression and a preparation method thereof. The food composition is prepared from the following components in parts by weight: 0.1 to 15 parts of casein hydrolyzed peptide, 0.01 to 1 part of a melissa officinalis extract, 0.01 to 1 part of a yellow chrysanthemum flower extract, 0.01 to 1 part of a radix valerianae extract, 0.01 to 1 part of a saffron crocus extract, 0.1 to 5 parts of a blueberry extract, 0.1 to 5 parts of a tremella fuciformis extract and 0.1 to 5 parts of a radix ginseng extract. The food composition can be prepared into tablets, oral liquid, powder and jelly by adding some adjuvants into the food composition. The traditional Chinese medicine with homology of medicine and food is combined with the raw materials of the modern new food technology, so that the food composition has the characteristics of multiple factors and multiple targets, is more targeted for treating or relieving depression, is safer to take and has no obvious toxic or side effect.

The invention discloses a traditional Chinese medicine prescription for treating depression. The traditional Chinese medicine prescription is prepared from the following raw materials by weight: 10 g-20 g of poria cocos, 2 g-4 g of acorus calamus, 2 g-4 g of liquorice, 7 g-11 g of bighead atractylodes rhizome, 10 g-20 g of raw jujube kernels, 2 g-4 g of polygala tenuifolia, 2 g-4 g of radix bupleuri, 7 g-11 g of angelica sinensis, 2 g-4 g of ginseng, 10 g-20 g of yam and 7 g-11 g of morinda officinalis. The poria cocos in the prescription has the effect of tranquilizing the heart; the acorus calamus can be used for treating unconscious mind, palpitation and amnesia; the raw jujube kernels have the effects of tranquilizing the heart and soothing the nerves and can be used for treating dysphoria and egersis; the polygala tenuifolia has the effects of tranquilizing the heart and developing intelligence and can be used for treating dysphoria, insomnia, dreaminess, amnesia, palpitation, trance and depression; and the radix bupleuri, the angelica sinensis, the ginseng, the Chinese yam and the morinda officinalis have an inhibition effect on depression; and the raw materials are all traditional Chinese medicines, so the traditional Chinese medicine prescription has small side effects on human bodies without causing the side effects of inappetence, mental drooping and the like.

Materials and Methods for identifying and measuring pharmacodynamic biomarkers of neuropsychiatric disease (e.g., major depressive disorder), stratifying disease severity, and monitoring a subject's response to treatment are provided.

There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and / or combinations thereof, for the treatment or alleviation of depression.